Markets
Auto insurance
Getty Images
Annoying!

Auto insurance prices have gone nuts

If you want to see the damage inflation can do, look no further.

Matt Phillips

It’s getting to be a bit much.

Auto insurance prices have surged over the last couple years. March consumer inflation out Wednesday shows them up 22% compared to last year. Since the end of 2019 — just before Covid hit — they’re up 45%.

Why? That’s where things get complicated.

In a prophylactic press release released Wednesday morning, an insurance industry trade group cited “greatly increased the cost of repairing and replacing cars” due to inflation. As anyone who has shopped for a new or used car over the last couple years can tell you, costs have gone up. That goes for the costs of replacing minor parts like bumpers or mirrors as well.

Insurers lost a lot of money on those replacement costs in 2021 and 2022, and are now trying to make that money back by raising rates a lot.

Then there’s also the the objectively atrocious driving record of Americans. Even before the pandemic, Americans were awful drivers compared to other high income countries, with auto death rates the highest among peer nations. High accident rates are reflected in higher costs of insurance.

And of course there’s also the old-fashioned profit motive. Insurers are trying to make money and raising rates is the way to do it.

“We will continue to pursue rate increases to restore profitability in states that are not yet at target margins,” Jesse Merten, chief financial officer at Allstate told an investor conference in early March. “And in other states, we'll take rate to keep pace with increases in loss costs.”

Wall Street seems pretty confident profits are on the way. Share prices of major auto insurers such as Allstate and Progressive, are hovering near all-time highs, and are handily outpacing the market this year, rising about 21% and 29%, compared to the 8% gain in the S&P 500.

More Markets

See all Markets
markets

Sandisk rides Wall Street price target hikes toward new record

Sandisk leapt Friday, riding a resurgent wave of AI-related market exuberance as well as two price target hikes from Wall Street analysts.

Goldman Sachs lifted its target for the stock to $320 from $280, while keeping a “buy” rating on the stock. Mizhuho lifted its target to a Street high of $410 from its previous target of $250, while maintaining an “outperform” rating on the shares.

Long considered a maker of commodity data storage products, Sandisk was spun off by Western Digital in an IPO in February.

When it dawned on the market sometime in the fall that the AI boom would mean an explosion in demand for data storage, Sandisk shares went parabolic.

Its more than 350% run-up between the ends of August and December led to Sandisk’s inclusion in the S&P 500. And its 560% gain for the year made it the index’s top performer.

markets
Luke Kawa

It looks like the stock market was expecting some tariff relief

The S&P 500 briefly dipped into negative territory and tariff-sensitive stocks swung from big gains to big losses after the Supreme Court declined to give a ruling on tariffs imposed by President Donald Trump under the IEEPA.

A basket of “Trump Tariff Losers” stocks compiled by UBS, which includes Under Armour, American Eagle, Yeti, Mattel, and Deckers Outdoor, was up as much as 1.5% in early trading before falling as much as 1.7% after news of the lack of news surfaced.

The good news is that for the market as a whole (and even this group in particular), the pain seems to have been short-lived, with both bouncing back to erase losses.

It’s a decent little snapshot or case study to show that, yes, as prediction markets imply, the stock market is pricing in tariff relief.

markets

Amazon pharmacy to begin offering home delivery for Novo Nordisk’s Wegovy pill

Amazon Pharmacy announced Friday that it will offer Novo Nordisk’s recently approved weight-loss pill Wegovy, the newest frontier in the drugmaker’s push toward direct-to-consumer options.

Amazon said it will offer delivery for the pill through insurance and cash-pay options. Novos cash-pay price for the pill is $149 a month — less than half of what its injectables cost through the same channel.

Novo has partnered with big-box stores like Costco and Walmart as well as several big telehealth companies, including Ro, Weight Watchers, and LifeMD, to distribute the pill. This comes as the Danish pharma giant is trying to regain ground after Eli Lilly surpassed it in market share, in large part because of its early emphasis on direct-to-consumer channels.

The Food and Drug Administration approved Novos weight-loss pill in December, making it the first approved weight-loss pill to go to market. It has the same active ingredient, semaglutide, as its injectable products, Ozempic and Wegovy. Lillys oral version, orforglipron, is expected to come to market later this year.

markets

Intel gains after a favorable post from Trump

Intel continued its strong 2026 start by rising early Friday, following a favorable online post from President Trump, whose administration partially nationalized the ailing American chip giant in August.

In a Truth Social post Thursday afternoon, he praised CEO Lip-Bu Tan, boasted about the amount of money the government’s 10% investment in the company has made, and said, “Our Country is determined to bring leading edge Chip Manufacturing back to America, and that is exactly what is happening!!!”

Even after adjusting for the Trumpian tendency toward hyperbole, that last comment will be intriguing to Intel watchers. The company’s search to make deals with external customers willing to use its next-generation contract chip manufacturing business, crucial to the future of Intel’s ailing foundry business, will likely be a key driver of the stock price this year.

It’s not nuts to think that having the US government as a shareholder and the president as an active cheerleader — especially one who’s not shy about putting pressure on private sector companies to get what he wants — could be helpful in corralling reticent foundry customers.

Intel is up roughly 16% year to date and has more than doubled over the last year.

Even after adjusting for the Trumpian tendency toward hyperbole, that last comment will be intriguing to Intel watchers. The company’s search to make deals with external customers willing to use its next-generation contract chip manufacturing business, crucial to the future of Intel’s ailing foundry business, will likely be a key driver of the stock price this year.

It’s not nuts to think that having the US government as a shareholder and the president as an active cheerleader — especially one who’s not shy about putting pressure on private sector companies to get what he wants — could be helpful in corralling reticent foundry customers.

Intel is up roughly 16% year to date and has more than doubled over the last year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.